VRTX"A quick trade for traders based on a classic, well-known pattern: Symmetrical Triangle. Entry at $500, stop loss at $460. First target between $527.5 _ $535. Second target between $544 _ $549."
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.65 EUR
3.28 B EUR
8.91 B EUR
256.90 M
About Vertex Pharmaceuticals Incorporated
Sector
CEO
Reshma Kewalramani
Headquarters
Boston
Website
Founded
1989
FIGI
BBG00KGFV1H9
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
VRTXThe VRTX stock has broken the ascending channel and successfully retested it. It is now ready to be sold with a first target between $404.60 and $403, and a second target of $375.50. The stop loss is at $500.
VRTX Vertex Pharmaceuticals Options Ahead of EarningsAnalyzing the options chain and the chart patterns of VRTX Vertex Pharmaceuticals prior to the earnings report this week,
I would consider purchasing the 472.5usd strike price Puts with
an expiration date of 2024-11-8,
for a premium of approximately $14.00.
If these options prove to be profitable pr
Vertex Pharmaceuticals (VRTX) | Chart & Forecast SummaryRight Here You Can See Vertex Pharmaceuticals Incorporated (VRTX) Registered As (VRTX) On The New York Stock Exchange, Vertex Pharmaceuticals Incorporated Is An American Biopharmaceutical Company Based In Boston, Massachusetts.
The Following Chart & Forecast Summary On Vertex Pharmaceuticals Incorp
VRTX Bull FlagVRTX is approaching the top end of bull flag on the 4hr. A break could lead to a move back up to ATH and beyond. The flag pole on this one is pretty big so if going on that projection it could see $600 if it does get continuation above.
A bearish scenario would be a rejection here at the top end or
Buy Vertex PharmaceuticalsShort Term Trading Advice by Naranj Capital
Buy Vertex Pharmaceuticals
● Buy Range- 475 - 480
● Target- 500 - 505
● StopLoss- 460
● Potential Return- 5-6%
● Duration- 12-14 Trading Days
VRTX upside?Beautiful bullflag breaking on the hourly and higher time frames, Targeting previous highs
Eyes on VRTXVRTX bouncing nicely off recent lows and has broken downtrend. Final confirmation would be a daily close over 421.50. Looking to enter a starter position and will add on a retest of the daily 48.
Vertex Pharmaceuticals pioneers with non-opioid painkiller VX-54Vertex Pharmaceuticals Inc., widely recognised for its cystic fibrosis treatments, is venturing into new therapeutic areas , signalling potential growth in new markets. The company is currently advancing its development of non-opioid analgesics, specifically candidate VX-548, which has demonstrated
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where 4VRTX is featured.
Frequently Asked Questions
The current price of 4VRTX is 446.60 EUR — it has increased by 0.94% in the past 24 hours. Watch VERTEX PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange VERTEX PHARMACEUTICALS stocks are traded under the ticker 4VRTX.
4VRTX stock has fallen by −0.02% compared to the previous week, the month change is a 2.10% rise, over the last year VERTEX PHARMACEUTICALS has showed a 18.62% increase.
We've gathered analysts' opinions on VERTEX PHARMACEUTICALS future price: according to them, 4VRTX price has a max estimate of 573.86 EUR and a min estimate of 309.81 EUR. Watch 4VRTX chart and read a more detailed VERTEX PHARMACEUTICALS stock forecast: see what analysts think of VERTEX PHARMACEUTICALS and suggest that you do with its stocks.
4VRTX reached its all-time high on Nov 5, 2024 with the price of 487.60 EUR, and its all-time low was 117.05 EUR and was reached on Dec 6, 2017. View more price dynamics on 4VRTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4VRTX stock is 0.93% volatile and has beta coefficient of 1.08. Track VERTEX PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is VERTEX PHARMACEUTICALS there?
Today VERTEX PHARMACEUTICALS has the market capitalization of 114.91 B, it has decreased by −1.69% over the last week.
Yes, you can track VERTEX PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
VERTEX PHARMACEUTICALS is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
4VRTX earnings for the last quarter are 3.93 EUR per share, whereas the estimation was 3.66 EUR resulting in a 7.41% surprise. The estimated earnings for the next quarter are 3.86 EUR per share. See more details about VERTEX PHARMACEUTICALS earnings.
VERTEX PHARMACEUTICALS revenue for the last quarter amounts to 2.49 B EUR, despite the estimated figure of 2.41 B EUR. In the next quarter, revenue is expected to reach 2.65 B EUR.
4VRTX net income for the last quarter is 938.92 M EUR, while the quarter before that showed −3.35 B EUR of net income which accounts for 127.99% change. Track more VERTEX PHARMACEUTICALS financial stats to get the full picture.
No, 4VRTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 5.40 K employees. See our rating of the largest employees — is VERTEX PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VERTEX PHARMACEUTICALS EBITDA is −79.13 M EUR, and current EBITDA margin is 45.32%. See more stats in VERTEX PHARMACEUTICALS financial statements.
Like other stocks, 4VRTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VERTEX PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VERTEX PHARMACEUTICALS technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VERTEX PHARMACEUTICALS stock shows the strong buy signal. See more of VERTEX PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.